<DOC>
	<DOCNO>NCT00634244</DOCNO>
	<brief_summary>This randomized phase II trial compare three different combination chemotherapy regimens see well work treat patient relapsed refractory acute myeloid leukemia . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . It yet know combination chemotherapy regimen effective treat patient relapsed refractory acute myeloid leukemia .</brief_summary>
	<brief_title>Comparing Three Different Combination Chemotherapy Regimens Treating Patients With Relapsed Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine complete remission ( CR ) + cytogenic complete remission ( CRc ) + morphologic complete remission incomplete blood count recovery ( CRi ) rate carboplatin topotecan ; flavopiridol , mitoxantrone cytosine arabinoside sirolimus , mitoxantrone , etoposide cytosine arabinoside adult patient refractory relapse acute myeloid leukemia ( AML ) . NOTE : Since CRc patient require either CR CRi , report rate CR+CRi result section . II . To determine rate treatment failure regimens . III . To determine incidence severity toxicity regimens . IV . To analyze predictive value blast cell property suggest determine response . ( Correlative laboratory study ) V. To determine whether pretreatment level B-cell chronic lymphocytic leukemia ( CLL ) /lymphoma 2 ( Bcl-2 ) , alternatively , whether therapy-induced change topoisomerase I level correlate response regimen . ( Correlative laboratory study ) VI . To assess impact clonal evolution compare cytogenetic abnormality time relapse initial diagnosis correlate abnormality change response treatment regimens protocol . ( Cytogenetic fluorescent situ hybridization [ FISH ] study ) VII . Panel FISH study common AML rearrangement perform relapse AML specimens determine presence recurrent AML abnormality evaluate subtle additional abnormality consistent clonal evolution relapse specimen . ( Cytogenetic FISH study ) OUTLINE : Patients randomize 1 3 treatment arm . INDUCTION THERAPY : ARM A : Patients receive carboplatin topotecan hydrochloride intravenously ( IV ) continuously 24 hour day 1-5 . ARM B : Patients receive alvocidib IV 4.5 hour daily ( QD ) day 1-3 , cytarabine IV continuously 72 hour day 6-8 , mitoxantrone hydrochloride IV 1-2 hour day 9 . ARM C : Patients receive sirolimus orally ( PO ) QD day 2-9 , mitoxantrone hydrochloride IV 15 minute QD , etoposide IV 1 hour QD , cytarabine IV 3 hour QD day 4-8 5-9 . ( Closed accrual ) After completion induction therapy , patient arm undergo bone marrow aspirate biopsy . Patients persistent leukemia ( i.e. , leukemic blast &gt; = 10 % ) remove study offer alternative therapy discretion investigator . Patients achieve CR proceed consolidation therapy receive alternative therapy discretion investigator . CONSOLIDATION THERAPY : Beginning within 2-6 week documentation CR , patient may receive 2 additional course treatment receive induction therapy . Courses repeat every 4-10 week absence disease progression unacceptable toxicity . After completion study therapy , patient follow periodically 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Inclusion Criteria Induction Therapy : Patients must morphologic proof ( bone marrow aspirate , smear touch prep marrow biopsy ) acute myelogenous leukemia ( AML ) &gt; = 10 % blast within two week prior induction randomization NOTE : Patients must register E3903 ( Ancillary Laboratory Protocol Collecting Diagnostic Material Patients Considered Eastern Cooperative Oncology Group [ ECOG ] American College Radiology Imaging Network [ ACRIN ] Treatment Trials Leukemia Related Hematologic Disorders ) must undergo eligibility test study multiparameter flow cytometry All immunodiagnoses eligible E1906 , except acute promyelocytic leukemia ( APL ) ( proven presence promyelocytic leukemia ( PML ) /retinoic acid receptor ( RAR ) alpha ) ; case APL become eligible patient ineligible ECOGACRIN APL trial alltrans retinoic acid arsenic trioxide plan part treatment regimen Patients must qualify one following : Relapse = &lt; 6 month first CR , date documentation CR documentation relapse Relapse 612 month first CR Refractory conventional initial induction chemotherapy ( = &lt; 2 course ) first reinduction ( = &lt; 1 course ) Normal cardiac ejection fraction pretreatment multi gate acquisition scan ( MUGA ) echocardiogram within 4 week prior randomization ( rest ejection fraction &gt; = 50 % &gt; = 5 % increase exercise ) , shorten fraction echocardiogram &gt; = 24 % , within normal range value institution Prior treatment dose follow : &lt; 300 mg/m^2 doxorubicin &lt; 300 mg/m^2 daunorubicin &lt; 100 mg/m^2 idarubicin &lt; 100 mg/m^2 mitoxantrone Serum creatinine = &lt; 2.0 mg/dL Serum direct bilirubin &lt; 2.0 mg/dL Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) &lt; 4 x upper limit normal The stipulation normal hepatic function apply liver dysfunction due leukemia infiltration Prior study entry , patient must recover toxicity prior chemotherapy radiotherapy ; patient refractory induction chemotherapy ( patient subgroup outline ) , marrow documentation residual leukemia post chemotherapy qualification remain eligibility criterion need prior study entry ( require &gt; = 30 % marrow blast evident minimum 10 % blast must present marrow ) NOTE : Hydroxyurea permit within 4 week study entry ECOG performance status 0 , 1 2 Patients history central nervous system ( CNS ) leukemia eligible documentation current CNS involvement cerebrospinal fluid ( CSF ) examination , ( i.e. , negative CSF lumbar puncture ) Consolidation therapy : Patients must ECOG performance status 0 , 1 2 Patients must document CR Patients must absence infection infection control antibiotic ; patient septic exclude Patients must serum creatinine clearance &gt; 50 cc/minute Patients must serum direct bilirubin &lt; 2.0 mg/dl alkaline phosphatase SGOT ( AST ) &lt; 4 x upper limit normal Patients must normal cardiac ejection fraction MUGA echocardiogram prior consolidation ( rest ejection fraction &gt; = 50 % &gt; = 5 % increase exercise ) , shorten fraction echocardiogram &gt; = 24 % , within normal range value institution prior first second cycle consolidation arm B C Exclusion Criteria Induction therapy : Patients relapse &gt; 1 year achieve first CR &gt; = second relapse Patients prior allogeneic OR autologous stem cell transplant History recent myocardial infarction ( within three month ) , uncontrolled congestive heart failure , uncontrolled cardiac arrhythmia Prior treatment carboplatin , topotecan , flavopiridol , sirolimus Pregnant breast feeding . Women childbearing potential sexually active male use accepted effective method contraception Intercurrent organ damage medical problem would prohibit therapy ; active unresolved infection Current evidence invasive fungal infection ; evidence include positive blood deep tissue culture stain Have another ( i.e. , prior ) tumor currently active likely interfere patient 's treatment AML likely compromise patient 's morbidity mortality substantially Consolidation therapy : Intercurrent organ damage medical problem jeopardize outcome therapy For arm B C , patient exceed follow anthracycline dose equivalent : &lt; 300 mg/m^2 doxorubicin &lt; 300 mg/m^2 daunorubicin &lt; 100 mg/m^2 idarubicin &lt; 100 mg/m^2 mitoxantrone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Acute Myelogenous Leukemia ( AML ) , Carboplatin , Topotecan , Flavopiridol , Mitoxantrone , Cytosine Arabinoside , Sirolimus , Etoposide</keyword>
</DOC>